GE HealthCare Technologies Inc. filings document formal disclosures for a medical technology and diagnostics company, including Form 8-K reports on results of operations and financial condition, material agreements, capital-structure matters, and governance changes. Recent current reports include earnings releases, a senior unsecured revolving credit facility, and board-related disclosures.
The company’s proxy materials describe annual-meeting matters, director elections, board committee assignments, executive compensation, equity awards, and shareholder voting procedures. GEHC filings also provide formal context for segment performance, liquidity arrangements, credit covenants, and governance matters tied to its healthcare technology, software, and pharmaceutical diagnostics businesses.
GE HealthCare Technologies Inc. (GEHC) announced that its Board of Directors has appointed Pascal Desroches to serve as a director, effective January 4, 2027. He will also join the Board’s Audit Committee and the Talent, Culture, and Compensation Committee on that date.
Desroches is Senior Executive Vice President and Chief Financial Officer of AT&T and plans to retire from AT&T on December 31, 2026. He brings more than 30 years of leadership experience in finance, governance, and large-scale technology and digital transformation, including prior roles at WarnerMedia, Turner Broadcasting, KPMG, the U.S. Securities and Exchange Commission, Honeywell Aerospace, the Federal Reserve Bank of Dallas, and DaVita. As a non-employee director, he will receive compensation under GE HealthCare’s existing non-employee director compensation program and will enter into the company’s standard indemnification agreement.
GE HealthCare Technologies Inc. (GEHC) reported that its Chief Financial Officer, William K. Grogan, received equity awards on September 14, 2026. He was granted 31,877 employee stock options with an exercise price of $64.25 per share, expiring September 14, 2036, which will become exercisable in three annual installments beginning September 2, 2027.
Grogan also received 62,256 restricted stock units, of which 50% vest on September 14, 2027 and 50% on September 14, 2028, and a separate award of 12,840 restricted stock units vesting 33% on September 2, 2027, 33% on September 2, 2028, and 34% on September 2, 2029. Each restricted stock unit represents one share of GE HealthCare common stock at settlement. No Rule 10b5-1 trading plan is reported for these awards.
GE HealthCare Technologies Inc. (GEHC) had its Chief Financial Officer, William K. Grogan, file an initial statement of beneficial ownership of securities. The filing reports no transactions, no current holdings of company securities, and references an attached power of attorney authorizing filings on his behalf.
GE HealthCare Technologies Inc. (GEHC) reported that officer Philip Rackliffe, CEO of AIS, had 798 shares of common stock withheld on September 3, 2026 to pay tax withholding obligations triggered by the vesting of restricted stock units. The shares were valued at $70.56 per share for this purpose, and Rackliffe now holds 41,533 shares of GE HealthCare common stock directly. No Rule 10b5-1 trading plan is reported for this transaction.
GE HealthCare Technologies Inc. (GEHC) reported that Kevin Michael O'Neill, CEO, PDx, had shares withheld on September 3, 2026 to cover tax obligations from vesting equity. 718 shares of common stock were withheld at $70.56 per share as payment of tax liability in connection with restricted stock units vesting. Following this, he holds 32,026 shares directly and 59 shares indirectly through a share incentive plan trust. No Rule 10b5-1 trading plan is reported.
GE HealthCare Technologies Inc. (GEHC) reported that Chief Accounting Officer George A. Newcomb had 112 shares of common stock withheld on September 3, 2026 to satisfy tax withholding obligations in connection with the vesting of restricted stock units. After this withholding, he holds 10,515 shares directly and 12 shares indirectly through a family member. No Rule 10b5-1 trading plan is reported for these transactions.
GE HealthCare Technologies Inc. (GEHC) reported that Chief Technology Officer Taha Kass-Hout had 1,502 shares of common stock withheld on September 3, 2026 to satisfy tax withholding obligations upon the vesting of restricted stock units. This tax-related disposition left him holding 88,467 shares of GE HealthCare common stock directly.
GE HealthCare Technologies Inc. (GEHC) reported that its General Counsel and Corporate Secretary, Frank R. Jimenez, had 1,480 shares of common stock withheld on September 3, 2026 to satisfy tax withholding obligations arising from the vesting of restricted stock units. This was recorded as a disposition related to tax withholding, not an open-market sale, at a value of $70.56 per share, leaving him with 89,321 shares of GE HealthCare common stock held directly.
GE HealthCare Technologies Inc. (GEHC) reported that Chief People Officer Adam Y. Holton had 673 shares of common stock withheld on September 3, 2026 to satisfy tax withholding obligations arising from the vesting of restricted stock units. This tax-withholding share disposition occurred without a Rule 10b5-1 trading plan and left him holding 19,533 shares directly.
GE HealthCare Technologies Inc. (GEHC) reported that Chief Commercial & Growth Officer Catherine Estrampes had shares withheld to cover taxes related to equity compensation. On September 3, 2026, 508 shares of common stock were disposed of at $70.56 per share to satisfy tax withholding obligations upon the vesting of restricted stock units. After this withholding transaction, she held 23,573 shares of GE HealthCare common stock directly.